AdaptHealth (AHCO) has drawn fresh attention after recent share performance, with returns of 28% over the past month and 19% over the past 3 months. This has prompted investors to reassess the home medical equipment provider.

The recent 27.8% 1 month share price return and 30.9% year to date share price return sit alongside a 62.5% 1 year total shareholder return. This suggests momentum has been building after earlier years of weaker results.

If AdaptHealth’s move has caught your attention and you want to widen your search in healthcare, it could be worth checking a screener of 36 healthcare AI stocks

With AdaptHealth trading at US$12.66, an intrinsic value estimate that sits materially higher, and a small 2.7% gap to the average analyst target of US$13.00, is there still a potential opportunity here or is the market already pricing in future growth?

Most Popular Narrative: 25.5% Undervalued

At a last close of $12.66 versus a narrative fair value of $17.00, the most followed view sees AdaptHealth trading at a sizeable discount and ties that gap to long term contract and efficiency upside.

Analysts broadly agree the new $1+ billion, five-year capitated contract will provide ~$200 million in annual recurring revenue once ramped, but this likely understates the upside: management expects significant halo effects as new sales infrastructure is established in untapped geographies, with resulting cross-sell opportunities that could drive contract-related revenue and profit well beyond guided levels over time, accelerating topline revenue growth and enterprise EBITDA above consensus.

Read the complete narrative. Read the complete narrative.

Want to see what is baked into that $17.00 figure? The narrative leans on faster revenue compounding, a swing from losses to profits, and a different earnings multiple than today. The full set of assumptions shows how those moving parts fit together and what needs to happen for the valuation gap to close.

Result: Fair Value of $17.00 (UNDERVALUED)

However, the bullish story could be challenged if CMS reimbursement cuts bite harder than expected, or if execution on large capitated contracts pressures margins instead of supporting them.

Another Take Using Sales Based Valuation

So far, the focus has been on analyst narratives and a fair value of $17.00, but the current price also lines up with a more down to earth sales based view. AdaptHealth trades on a P/S of 0.5x, which is identical to peers at 0.5x and slightly below its own fair ratio of 0.6x. That leans toward modestly attractive rather than obviously cheap, so the question is whether you see that small gap as enough compensation for the business risks outlined earlier.

Next Steps

If the mixed sentiment in this article has you weighing both sides, act while the details are fresh and review what the data is telling you by checking the 2 key rewards.

Looking for more investment ideas?

AdaptHealth might be on your radar now, but you do not want your next opportunity to slip past while you are only watching one stock.

• Spot potential value opportunities early by scanning a curated set of screener containing 23 high quality undiscovered gems that many investors may not be watching yet.
• Prioritise resilience by focusing on companies highlighted in the 71 resilient stocks with low risk scores so your portfolio is not leaning too hard on fragile names.
• Build a list of quality names with stronger finances by reviewing the solid balance sheet and fundamentals stocks screener (42 results) before capital gets tied up elsewhere.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.